However, taking into account the current diagnostic standards of patients with ovarian cancer in the context of determining the optimal treatment and qualifying patients for treatment with PARP inhibitors, the BRCA1/2 gene is routinely tested using the NGS method in DNA extracted from tumour cells. The gene discussed is BRCA1; the disease is ovarian carcinoma.